FY2025 EPS Estimate for Sanara MedTech Increased by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI) – Research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Sanara MedTech in a note issued to investors on Thursday, August 14th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($0.88) per share for the year, up from their previous estimate of ($1.78). The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. Cantor Fitzgerald also issued estimates for Sanara MedTech’s FY2026 earnings at ($0.16) EPS.

Separately, HC Wainwright upped their price target on Sanara MedTech from $53.00 to $54.00 and gave the company a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $50.00.

Sanara MedTech Trading Down 2.3%

NASDAQ:SMTI opened at $30.86 on Monday. Sanara MedTech has a 1 year low of $23.53 and a 1 year high of $39.08. The stock has a market cap of $274.65 million, a P/E ratio of -26.60 and a beta of 1.26. The company has a debt-to-equity ratio of 1.25, a quick ratio of 2.03 and a current ratio of 2.26. The stock has a 50-day simple moving average of $27.74 and a 200-day simple moving average of $30.38.

Sanara MedTech (NASDAQ:SMTI) last posted its earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.10. Sanara MedTech had a negative return on equity of 26.43% and a negative net margin of 10.22%.The firm had revenue of $25.83 million for the quarter, compared to analyst estimates of $25.15 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP lifted its stake in Sanara MedTech by 144.3% in the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after buying an additional 42,237 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Sanara MedTech by 152.9% during the fourth quarter. Renaissance Technologies LLC now owns 35,400 shares of the company’s stock worth $1,175,000 after acquiring an additional 21,400 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Sanara MedTech in the 2nd quarter valued at $382,000. Nuveen LLC purchased a new stake in Sanara MedTech in the 1st quarter valued at $326,000. Finally, JPMorgan Chase & Co. boosted its stake in Sanara MedTech by 234.5% during the 4th quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company’s stock worth $451,000 after purchasing an additional 9,516 shares during the period. Hedge funds and other institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.